Goldman Sachs’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
SCM
S
Goldman Sachs's NVAX Position: Q2 2026 in Review
Goldman Sachs increased its Novavax (NVAX) stake by 113% in Q2 2026, buying an estimated $14.3M and bringing the position to 3,007,756 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2323.
Goldman Sachs first reported a position in NVAX in Q2 2013 and has held it in 53 quarters since. The position peaked at $139M in Q1 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Goldman Sachs held 3,007,756 shares of Novavax worth $28.3M as of Q2 2026.
- Goldman Sachs bought 1,598,310 Novavax shares in Q2 2026, an estimated $14.3M.
- Novavax made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2323 holding.
- Goldman Sachs first reported a position in Novavax in Q2 2013 and has held it in 53 quarters since.
- Goldman Sachs's Novavax position peaked at $139M in Q1 2021.
- 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.